Watch for · Read the offer closely
A claim can sound clear while leaving the important part out. What would you need to know before taking it further?
Claims worth stopping at
As of September 2026, a prescription orders medicine and must come from a health professional with permission to prescribe under federal law.
A prescription medicine cannot be supplied without that order.
An offer that skips that order is a reason to pause.
FDA stands for Food and Drug Administration, a US agency whose work includes reviewing medicines.
As of September 2026, the FDA warns about products offered for weight loss with labels saying they are for research.
Some sellers also give people instructions for taking these products. Their quality is unknown, and the FDA says they may cause harm.
Retatrutide and cagrilintide are ingredient names to ask about when an offer promises weight loss.
Look for these names in the offer’s ingredient list, or ask the seller to name every ingredient.
As of September 2026, the FDA says neither ingredient is part of an FDA-approved medicine.
The FDA says federal law bars the use of retatrutide or cagrilintide in medicines made to order, as of September 2026.
Compounded means made or mixed to order.
As of September 2026, FDA guidance treats claims of FDA approval for a made-to-order medicine as false or misleading.
“FDA registered” can mean a company has added the place where it makes medicines to FDA records.
A medicine may also be listed in those records. Neither entry means the FDA has approved the facility or the medicine, as of September 2026.
As of September 2026, the FDA describes fake products offered for weight loss with labels naming pharmacies that do not exist.
Ask which pharmacy made it, then check the name through Georgia’s pharmacy board.
The label and the delivery
GLP-1 comes from the body and helps regulate blood sugar and appetite.
The ingredients semaglutide (in Ozempic and Wegovy) and tirzepatide (in Mounjaro and Zepbound) copy GLP-1’s effects to treat diabetes or help control weight.
For GLP-1 shots, the FDA advises against using medicine delivered warm or without adequate cold storage, as of September 2026.
Storage needs depend on the product. The label and pharmacy’s instructions matter; there is no cold-storage rule for all peptides.
As of September 2026, FDA reports describe people needing hospital care after errors measuring semaglutide shots made to order.
“Who will explain the instructions, and how can I reach them if the label or delivery is confusing?”
If an offer has gone wrong
For a doctor or physician assistant, Georgia’s medical board accepts care complaints but does not settle fee disputes.
For pharmacy practice, the Georgia pharmacy board has a complaint route.
For deceptive sales, Georgia’s Consumer Protection Division accepts complaints and can refer issues that belong with another agency.